InvestorsHub Logo
Followers 30
Posts 1475
Boards Moderated 0
Alias Born 07/10/2013

Re: changes_iv post# 42181

Monday, 09/06/2021 7:29:59 PM

Monday, September 06, 2021 7:29:59 PM

Post# of 44690
On February 23, NeuroRx said the Phase IIb/III COVID-AIV trial (NCT04311697) of Zyesami (aviptadil, previously RLF-100™) for the treatment of respiratory failure in critically ill patients with COVID-19 has shown multidimensional benefit around its prespecified primary endpoint of recovery from respiratory failure with discharge from hospital and ICU (without relapse) by day 28 in patients with critical COVID-19 who were treated with High Flow Nasal Oxygen. The trial was conducted at 10 U.S. hospitals under the direction of NeuroRx and its Swiss partner Relief Therapeutics.

https://www.genengnews.com/covid-19-candidates/relief-therapeutics/

NRx Pharmaceuticals has reported additional data from Phase IIb/III clinical trial where its drug, Zyesami (aviptadil), offered a rise in blood oxygen within a day in critical Covid-19 patients with acute respiratory failure.

Zyesami is a synthetic form of vasoactive intestinal polypeptide (VIP), which attaches selectively to the alveolar type II cell (ATII) in the air sac (alveolus) of the lung.

The latest analysis results showed that subjects receiving Zyesami had improvement in blood oxygen, which signifies improved lung function, within a day of commencing therapy.


“The benefit was seen across all patients, all baseline severities, and all types of hospitals.

“We believe this new finding illustrates Zyesami’s mechanism of action in a placebo-controlled trial and supports our application for breakthrough therapy designation to the FDA.”

https://www.pharmaceutical-technology.com/news/nrx-zyesami-covid-trial/